Reassessing carbamazepine in the treatment of bipolar disorder: Clinical implications of new data

David L. Ginsberg, Hagop S. Akiskal, Paul E. Keck, Matthew A. Fuller, Richard H. Weisler, Robert M A Hirschfeld, Eric Hollander

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

This monograph summarizes the proceedings of a roundtable meeting convened to discuss the role of carbamazepine in the treatment of bipolar disorder, in light of new data and the recent indication of carbamazepine extended-release capsules (CBZ ERC) for use in the treatment of acute manic and mixed episodes. Two lectures were presented, followed by a panel discussion among all 6 participants. A summary of the two pivotal trials of CBZ ERC and their pooled data along with other relevant data is presented first. Next, historical trends of carbamazepine and the agent's use in acute mania, bipolar depression, and maintenance are reviewed, emphasizing clinical implications of efficacy, safety, tolerability, and drug interactions. Finally, the panel discussion provides recommendations for the use of carbamazepine in different phases of the illness, taking into account adverse effects and drug-drug interactions. Panel discussants agree that current data confirm the utility of CBZ ERC as an effective treatment for acute manic and mixed episodes in bipolar disorder. Carbamazepine may also prove to be an option for maintenance treatment. Tolerability of the drug is related to dose and titration, and overall safety limitations regarding carbamazepine usage are comparable to other medications. For some patients, the main challenges to use of carbamazepine may be common drug-drug interactions and increased side effects related to aggressive introduction during treatment of acute manic and mixed episodes. Thus, carbamazepine may be a lower priority option for patients who are taking multiple medications, such as elderly individuals with medical comorbidity, due to the potential for drug interactions. Important benefits of carbamazepine include the low propensity toward weight gain and evidence of good tolerability with long-term treatment. (At present there are no available data from long-term, placebo-controlled studies evaluating the effects of carbamazepine or CBZ ERC on weight.) Thus, carbamazepine may be a good option for patients who are concerned about weight gain or who are intolerant of or respond poorly to other medications. Further efforts are needed to update physicians on the use of carbamazepine relative to other medications in the treatment of bipolar disorder.

Original languageEnglish (US)
Pages (from-to)1-14
Number of pages14
JournalCNS Spectrums
Volume10
Issue number6
StatePublished - Jun 2005

Fingerprint

Carbamazepine
Bipolar Disorder
Drug Interactions
Therapeutics
Capsules
Weight Gain
Pharmaceutical Preparations
Safety
Comorbidity

ASJC Scopus subject areas

  • Neuropsychology and Physiological Psychology

Cite this

Ginsberg, D. L., Akiskal, H. S., Keck, P. E., Fuller, M. A., Weisler, R. H., Hirschfeld, R. M. A., & Hollander, E. (2005). Reassessing carbamazepine in the treatment of bipolar disorder: Clinical implications of new data. CNS Spectrums, 10(6), 1-14.

Reassessing carbamazepine in the treatment of bipolar disorder : Clinical implications of new data. / Ginsberg, David L.; Akiskal, Hagop S.; Keck, Paul E.; Fuller, Matthew A.; Weisler, Richard H.; Hirschfeld, Robert M A; Hollander, Eric.

In: CNS Spectrums, Vol. 10, No. 6, 06.2005, p. 1-14.

Research output: Contribution to journalArticle

Ginsberg, DL, Akiskal, HS, Keck, PE, Fuller, MA, Weisler, RH, Hirschfeld, RMA & Hollander, E 2005, 'Reassessing carbamazepine in the treatment of bipolar disorder: Clinical implications of new data', CNS Spectrums, vol. 10, no. 6, pp. 1-14.
Ginsberg DL, Akiskal HS, Keck PE, Fuller MA, Weisler RH, Hirschfeld RMA et al. Reassessing carbamazepine in the treatment of bipolar disorder: Clinical implications of new data. CNS Spectrums. 2005 Jun;10(6):1-14.
Ginsberg, David L. ; Akiskal, Hagop S. ; Keck, Paul E. ; Fuller, Matthew A. ; Weisler, Richard H. ; Hirschfeld, Robert M A ; Hollander, Eric. / Reassessing carbamazepine in the treatment of bipolar disorder : Clinical implications of new data. In: CNS Spectrums. 2005 ; Vol. 10, No. 6. pp. 1-14.
@article{91a6f2d15d1c4528a6f9d9e0a500a7a0,
title = "Reassessing carbamazepine in the treatment of bipolar disorder: Clinical implications of new data",
abstract = "This monograph summarizes the proceedings of a roundtable meeting convened to discuss the role of carbamazepine in the treatment of bipolar disorder, in light of new data and the recent indication of carbamazepine extended-release capsules (CBZ ERC) for use in the treatment of acute manic and mixed episodes. Two lectures were presented, followed by a panel discussion among all 6 participants. A summary of the two pivotal trials of CBZ ERC and their pooled data along with other relevant data is presented first. Next, historical trends of carbamazepine and the agent's use in acute mania, bipolar depression, and maintenance are reviewed, emphasizing clinical implications of efficacy, safety, tolerability, and drug interactions. Finally, the panel discussion provides recommendations for the use of carbamazepine in different phases of the illness, taking into account adverse effects and drug-drug interactions. Panel discussants agree that current data confirm the utility of CBZ ERC as an effective treatment for acute manic and mixed episodes in bipolar disorder. Carbamazepine may also prove to be an option for maintenance treatment. Tolerability of the drug is related to dose and titration, and overall safety limitations regarding carbamazepine usage are comparable to other medications. For some patients, the main challenges to use of carbamazepine may be common drug-drug interactions and increased side effects related to aggressive introduction during treatment of acute manic and mixed episodes. Thus, carbamazepine may be a lower priority option for patients who are taking multiple medications, such as elderly individuals with medical comorbidity, due to the potential for drug interactions. Important benefits of carbamazepine include the low propensity toward weight gain and evidence of good tolerability with long-term treatment. (At present there are no available data from long-term, placebo-controlled studies evaluating the effects of carbamazepine or CBZ ERC on weight.) Thus, carbamazepine may be a good option for patients who are concerned about weight gain or who are intolerant of or respond poorly to other medications. Further efforts are needed to update physicians on the use of carbamazepine relative to other medications in the treatment of bipolar disorder.",
author = "Ginsberg, {David L.} and Akiskal, {Hagop S.} and Keck, {Paul E.} and Fuller, {Matthew A.} and Weisler, {Richard H.} and Hirschfeld, {Robert M A} and Eric Hollander",
year = "2005",
month = "6",
language = "English (US)",
volume = "10",
pages = "1--14",
journal = "CNS Spectrums",
issn = "1092-8529",
publisher = "MBL Communications",
number = "6",

}

TY - JOUR

T1 - Reassessing carbamazepine in the treatment of bipolar disorder

T2 - Clinical implications of new data

AU - Ginsberg, David L.

AU - Akiskal, Hagop S.

AU - Keck, Paul E.

AU - Fuller, Matthew A.

AU - Weisler, Richard H.

AU - Hirschfeld, Robert M A

AU - Hollander, Eric

PY - 2005/6

Y1 - 2005/6

N2 - This monograph summarizes the proceedings of a roundtable meeting convened to discuss the role of carbamazepine in the treatment of bipolar disorder, in light of new data and the recent indication of carbamazepine extended-release capsules (CBZ ERC) for use in the treatment of acute manic and mixed episodes. Two lectures were presented, followed by a panel discussion among all 6 participants. A summary of the two pivotal trials of CBZ ERC and their pooled data along with other relevant data is presented first. Next, historical trends of carbamazepine and the agent's use in acute mania, bipolar depression, and maintenance are reviewed, emphasizing clinical implications of efficacy, safety, tolerability, and drug interactions. Finally, the panel discussion provides recommendations for the use of carbamazepine in different phases of the illness, taking into account adverse effects and drug-drug interactions. Panel discussants agree that current data confirm the utility of CBZ ERC as an effective treatment for acute manic and mixed episodes in bipolar disorder. Carbamazepine may also prove to be an option for maintenance treatment. Tolerability of the drug is related to dose and titration, and overall safety limitations regarding carbamazepine usage are comparable to other medications. For some patients, the main challenges to use of carbamazepine may be common drug-drug interactions and increased side effects related to aggressive introduction during treatment of acute manic and mixed episodes. Thus, carbamazepine may be a lower priority option for patients who are taking multiple medications, such as elderly individuals with medical comorbidity, due to the potential for drug interactions. Important benefits of carbamazepine include the low propensity toward weight gain and evidence of good tolerability with long-term treatment. (At present there are no available data from long-term, placebo-controlled studies evaluating the effects of carbamazepine or CBZ ERC on weight.) Thus, carbamazepine may be a good option for patients who are concerned about weight gain or who are intolerant of or respond poorly to other medications. Further efforts are needed to update physicians on the use of carbamazepine relative to other medications in the treatment of bipolar disorder.

AB - This monograph summarizes the proceedings of a roundtable meeting convened to discuss the role of carbamazepine in the treatment of bipolar disorder, in light of new data and the recent indication of carbamazepine extended-release capsules (CBZ ERC) for use in the treatment of acute manic and mixed episodes. Two lectures were presented, followed by a panel discussion among all 6 participants. A summary of the two pivotal trials of CBZ ERC and their pooled data along with other relevant data is presented first. Next, historical trends of carbamazepine and the agent's use in acute mania, bipolar depression, and maintenance are reviewed, emphasizing clinical implications of efficacy, safety, tolerability, and drug interactions. Finally, the panel discussion provides recommendations for the use of carbamazepine in different phases of the illness, taking into account adverse effects and drug-drug interactions. Panel discussants agree that current data confirm the utility of CBZ ERC as an effective treatment for acute manic and mixed episodes in bipolar disorder. Carbamazepine may also prove to be an option for maintenance treatment. Tolerability of the drug is related to dose and titration, and overall safety limitations regarding carbamazepine usage are comparable to other medications. For some patients, the main challenges to use of carbamazepine may be common drug-drug interactions and increased side effects related to aggressive introduction during treatment of acute manic and mixed episodes. Thus, carbamazepine may be a lower priority option for patients who are taking multiple medications, such as elderly individuals with medical comorbidity, due to the potential for drug interactions. Important benefits of carbamazepine include the low propensity toward weight gain and evidence of good tolerability with long-term treatment. (At present there are no available data from long-term, placebo-controlled studies evaluating the effects of carbamazepine or CBZ ERC on weight.) Thus, carbamazepine may be a good option for patients who are concerned about weight gain or who are intolerant of or respond poorly to other medications. Further efforts are needed to update physicians on the use of carbamazepine relative to other medications in the treatment of bipolar disorder.

UR - http://www.scopus.com/inward/record.url?scp=21644450556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21644450556&partnerID=8YFLogxK

M3 - Article

C2 - 16041864

AN - SCOPUS:21644450556

VL - 10

SP - 1

EP - 14

JO - CNS Spectrums

JF - CNS Spectrums

SN - 1092-8529

IS - 6

ER -